Doxorubicin is an effective chemotherapeutic agent used against a wide spectrum of cancer types. Total lifetime exposure above a threshold dose is associated with increased risk of progressive heart failure, often years after treatment. To date, the mechanisms and genetic susceptibilities underlying this disease still remain unclear. The role of tumor protein p53 (encoded by human TP53 and mouse Trp53 genes) in doxorubicin-induced cardiomyopathy has been investigated previously with studies showing that p53-induced cell death promotes this cardiotoxicity. However, the majority of these studies used mouse models treated with bolus injections of high dose doxorubicin (~20 mg/kg) that cause acute cardiac dysfunction and high mortality within days after treatment. In the clinics, doxorubicin is given to cancer patients in divided lower doses over weeks due to its toxicity. Thus, the acute cell death caused by a bolus dose injection of doxorubicin in mice may not reflect the progressive dilated cardiomyopathy observed in patients. Furthermore, the time course of doxorubicin induced cardiomyopathy contrasts from the early onset heart failure caused by acute processes such as myocardial infarctions where ischemia-induced cardiomyocyte cell death clearly mediates pathogenesis.

Given this background of information, it was notable that an interesting study using mice treated with low divided doses of doxorubicin showed that p53 might have a protective role in preventing the late-onset cardiomyopathy. Consistent with its interference of DNA replication and transcription in cancer cells, doxorubicin has also been reported to cause mitochondrial DNA (mtDNA) damage, which can impair mitochondrial function and result in cardiac dysfunction. Besides inducing cell death as one way of maintaining nuclear genomic integrity, there is growing evidence that p53 can also act as guardian of the mitochondrial genome. Thus, p53 potentially has a dual nature: its acute cell death activity under severe genotoxic stress by high bolus doses of doxorubicin; and its mtDNA maintenance function that protects against late onset cardiomyopathy associated with doxorubicin given in low divided doses in the clinics.

Using 3 different Trp53 genotype mice with unique profiles of cellular activity, our recent study dissected the role of cell death versus non-death, including mitochondrial, activities of p53 in the later onset cardiomyopathy model (Figure 1). Mice with knockin of the Trp53 R172H mutation (p53R172H/H), homologous to the human TP53 R175H that causes early-onset cancer disorder Li-Fraumeni syndrome, retains mtDNA maintenance activity while losing cell death/cell cycle arrest activities as in the Trp53 null (p53−/−) state. Unlike the high bolus dose of doxorubicin, the low divided doses of doxorubicin did not increase the mortality of treated mice, permitting longer term measurement of their cardiac function. In contrast to both wild-type Trp53+/− and knockin mutant Trp53+/−/− mice, Trp53−/− mice began to show left ventricular (LV) dilatation and systolic dysfunction 4 wk after doxorubicin treatment in association with reduced mitochondrial metabolism. Mechanistically, both wild-type and R172H mutant Trp53 can promote the expression of Mitochondrial transcription factor A (TFAM) and p53-inducible ribonucleotide reductase 2 (RRM2B or p53R2), which are critical for mtDNA transcription and maintenance. In contrast to the cardiac tissue of Trp53+/− mice acutely exposed to bolus dosing of doxorubicin, samples from mice treated with low divided doses of doxorubicin did not show any detectable apoptosis, regardless of their Trp53 genotypes. Therefore, these 3 different Trp53 genotypes with unique cellular activities indicated that p53-regulated cell death pathways are unlikely to be involved in the development of late-onset cardiomyopathy induced by doxorubicin administered in a more clinically relevant manner.

The Trp53 genotype-dependent responses to doxorubicin treatment in the mouse models were also replicated in human iPSC cell-derived cardiomyocytes. Both wild-type and mutant R175H TP53 human iPSC cell-derived cardiomyocytes showed...
increased expression of TFAM and p53R2 while apoptosis was only evident with supra-clinical concentrations of doxorubicin in the wild-type state. On the other hand, lower concentrations of doxorubicin were sufficient to increase the transcript levels of mitochondrial respiratory subunits encoded by mtDNA in both wild-type and mutant TP53 cardiomyocytes while these increases were absent in the TP53 null state. Similar results were observed in doxorubicin treated human skeletal muscle myoblasts, suggesting their possible contribution to the mechanism of fatigue and peripheral muscle myopathy reported in patients treated with doxorubicin.

Prevention of mitochondrial and LV systolic dysfunction by the concurrent treatment of Trp53 null mice with nicotinamide mononucleotide (NMN) further supported the mechanism whereby mtDNA depletion underlies doxorubicin-induced cardiomyopathy. At the cellular signaling level, increasing tissue nicotinamide adenine dinucleotide (NAD$^+$) content by NMN has been reported to increase the expression of TFAM for mtDNA homeostasis via NAD$^+$/sirtuin 1 (SIRT1)-mediated deacetylation and activation of PGC-1α, but this could also involve other SIRT family members.9

In summary, the present study provides genetic evidence that p53 has a protective effect on the mitochondrial genome of the heart after doxorubicin exposure and that its regulation of mtDNA transcription may be critical for preventing cardiotoxicity (Figure 1). Chromatin immunoprecipitation (ChIP) analysis in human myoblasts demonstrated that mutant p53 R175H can be recruited to an ETS2-binding site of TFAM via protein-protein interaction to increase its expression, analogous to a mechanism previously reported for the p53R2 gene.10 In this regard, the higher stability and levels of mutant p53 protein may contribute to the observed gain-of-function in mtDNA encoded respiratory subunit gene expression. Additionally, the decreased levels of mtDNA-encoded transcripts in peripheral blood cells of Trp53 null mice which is not the TP53 genetic background in the human disease. It is also well-known that small animals like mice are not ideal for modeling human cardiac pathophysiology, but nonetheless, they represent simple genetic models for gleaning mechanistic insights. The use of larger animals may be necessary to more closely model the human disease. Also, as expected based on the low incidence of the human disease, using divided doses of doxorubicin did not cause significant heart failure in mice with wild-type Trp53 within the time limits of our study due to early cancer development in Trp53 mutant states. Cardiac-specific Trp53 gene disruption may not only permit increasing the duration of follow up after doxorubicin treatment but also allow further investigations into whether mtDNA regulation by p53 in cardiomyocytes plays a cell-autonomous role in preventing doxorubicin-induced cardiomyopathy. Investigating the potential utility of prognostic blood markers and therapeutic interventions to promote mitochondrial biogenesis in future translational studies may be fruitful.

Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.

Funding
This work was supported by the Division of Intramural Research, NHLBI, NIH.

ORCID
Masahiro Nishi http://orcid.org/0000-0001-8593-3835

References
1. Dhingra R, Margules V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, Dorn GW, Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci USA. 2014;111:E5537–E5544. doi:10.1073/pnas.1414665111.
2. Fang X, Wang H, Han D, Xie E, Yang X, Wei J, Gu S, Gao F, Zhu N, Yin X, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA. 2019;116:2672–2680. doi:10.1073/pnas.1821022116.

3. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation. 2009;119:99–106. doi:10.1161/CIRCULATIONAHA.108.799700.

4. Zhu W, Zhang W, Shou W, Field LJ. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity. Cardiovasc Res. 2014;103:81–89. doi:10.1093/cvr/cvu118.

5. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436–444. doi:10.1002/path.1863.

6. Kamp WM, Wang PY, Hwang PM. TP53 mutation, mitochondria and cancer. Curr Opin Genet Dev. 2016;38:16–22. doi:10.1016/j.gde.2016.02.007.

7. Li J, Wang PY, Long NA, Zhuang J, Springer DA, Zou J, Lin Y, Bleck CKE, Park JH, Kang JG, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci USA. 2019;116:19626–19634. doi:10.1073/pnas.1904979116.

8. Wang PY, Ma W, Park JY, Celi FS, Arena R, Choi JW, Ali QA, Tripodi DJ, Zhuang J, Lago CU, et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med. 2013;368:1027–1032. doi:10.1056/NEJMoa1214091.

9. Chandrasekaran K, Anjaneyulu M, Choi J, Kumar P, Salimian M, Ho CY, Russel JW. Role of mitochondria in diabetic peripheral neuropathy: influencing the NAD(+)--dependent SIRT1-PGC-1alpha-TFAM pathway. Int Rev Neurobiol. 2019;145:177–209.

10. Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, et al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun. 2015;6:7389. doi:10.1038/ncomms8389.